Carmell Therapeutics Corp - Product Pipeline Analysis, 2018 Update
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Carmell Therapeutics Corp Company Overview 5
Carmell Therapeutics Corp Company Snapshot 5
Carmell Therapeutics Corp Pipeline Products and Ongoing Clinical Trials Overview 5
Carmell Therapeutics Corp – Pipeline Analysis Overview 8
Carmell Therapeutics Corp - Key Facts 8
Carmell Therapeutics Corp - Major Products and Services 9
Carmell Therapeutics Corp Pipeline Products by Development Stage 10
Carmell Therapeutics Corp Pipeline Products Overview 12
Bone Healing Accelerant - DBM Spine 12
Bone Healing Accelerant - DBM Spine Product Overview 12
Bone Healing Accelerant - Long Bone (Tibia) Fractures 13
Bone Healing Accelerant - Long Bone (Tibia) Fractures Product Overview 13
Bone Healing Accelerant - Shoulder Repair 14
Bone Healing Accelerant - Shoulder Repair Product Overview 14
Bone Healing Accelerant - Total Joint Replacement 15
Bone Healing Accelerant - Total Joint Replacement Product Overview 15
REPAIR Surgical Scaffold 16
REPAIR Surgical Scaffold Product Overview 16
Tissue Healing Accelerant - C-Section/Hysterectomy 17
Tissue Healing Accelerant - C-Section/Hysterectomy Product Overview 17
Tissue Healing Accelerant - Chronic Wound Beds 18
Tissue Healing Accelerant - Chronic Wound Beds Product Overview 18
Tissue Healing Accelerant - Colorectal Surgery 19
Tissue Healing Accelerant - Colorectal Surgery Product Overview 19
Tissue Healing Accelerant - Partial And Full Thickness Grafts 20
Tissue Healing Accelerant - Partial And Full Thickness Grafts Product Overview 20
Tissue Healing Accelerant - Sternotomy 21
Tissue Healing Accelerant - Sternotomy Product Overview 21
Tissue Healing Accelerant - Surgical Wound Healing 22
Tissue Healing Accelerant - Surgical Wound Healing Product Overview 22
Carmell Therapeutics Corp - Key Competitors 23
Carmell Therapeutics Corp - Key Employees 24
Carmell Therapeutics Corp - Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Carmell Therapeutics Corp, Recent Developments 26
Jun 22, 2017: Carmell Therapeutics announced the issuance of Canadian Patent No. 2701187 for METHODS AND APPARATUS FOR MANUFACTURING PLASMA BASED PLASTICS 26
Jun 22, 2017: Carmell Therapeutics announced the issuance of Canadian Patent No. 2701187 for Methods and Apparatus for Manufacturing Plasma Based Plastics 26
May 09, 2017: Carmell Therapeutics expands manufacturing capabilities to support Phase III clinical trials 27
Oct 05, 2016: Carmell Therapeutics New Management Team 27
Jun 24, 2016: Carmell announces the awarding of a new U.S. Patent that covers the use of the Company’s plasma-based materials as drug delivery vehicles 28
Apr 07, 2016: Dr. James Hart joins Carmell Therapeutics as new Chief Medical Officer 28
Feb 16, 2016: Carmell Therapeutics Announces Appointment of Randy Hubbell to President and Chief Executive Officer 28
May 15, 2015: Carmell Therapeutics’ Plasma-Based Materials Shown to be Effective Antibiotic Delivery Vehicles 29
Dec 23, 2014: Carmell Therapeutics Ends 2014 with Addition of a New Patent to its Growing Portfolio 29
Nov 14, 2014: Pittsburgh researchers' bone putty could revolutionize how broken bones mend 30
Appendix 31
Methodology 31
About GlobalData 34
Contact Us 34
Disclaimer 34
Summary
Carmell Therapeutics Corp (Carmell) is a biotechnology company that develops and commercializes bone healing accelerants and tissue healing accelerants. Its pipeline portfolio include adjunctive treatment for long bone fractures in Phase I and Phase II a; and adjunctive treatment for total joint replacement; enhancer and extender for demineralized bone spine; and tissue healing accelerants to reduce surgical site infections in colorectal surgery, sternotomy, cesarean section, and hysterectomy in preclinical phase. Carmell’s pipeline products are based on its patented plasma-based bioactive materials (PBMs). The company caters its products to surgical site infection and orthopedic markets. Carmell is headquartered in Pittsburgh, Pennsylvania, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Carmell Therapeutics Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company